Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Relative Bioavailability Study of HNC364 Injectable Suspension
Details : HNC364 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : HNC1058
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058
Details : HNC1058 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : HNC1058
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
Details : HNC364 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : HNC042
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Heilongjiang Zhenbaodao Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HNC042 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : HNC042
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Heilongjiang Zhenbaodao Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HNC664
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
Details : HNC664 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : HNC664
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HNC042
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.
Details : HNC042 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 14, 2018
Lead Product(s) : HNC042
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable